As America’s #1 provider of 3-phase string inverters, CPS America is proud to showcase the latest innovations in solar and ...

Vibrance-1 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of alixorexton (formerly referred to as ALKS 2680) in adults with ...

– Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN, July 21, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the ...

The catchily named Eaton SMX1500XLRT2UN is a 2U high industrial UPS that can be rack mounted or floor standing, has power ...

Pfizer Inc. has initiated a new clinical study titled A Phase 1, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and ...

MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s ...

This article introduces a compact D-band phase shifter, which achieves high-resolution phase steps and ultra-low phase error, designed for the sixth-generation (6G) mobile network. The proposed design ...

Eyecyte-RPE phase 1 study showed promising safety and efficacy, with no serious adverse events and significant vision improvement in patients with geographic atrophy. The trial involved nine patients ...

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Cleveland Hopkins International Airport opened bidding for first stage of $1.1-billion airport expansion and modernization. The lead architect is Corgan and engineering consultant is Connico.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out why KYMR stock is a Strong Buy.

Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting –Favorable safety and tolerability, with ...